Drug delivery by red blood cells
暂无分享,去创建一个
Mauro Magnani | M. Magnani | L. Rossi | A. Fraternale | Sara Biagiotti | S. Biagiotti | Luigia Rossi | Maria Filomena Paoletti | Alessandra Fraternale | M. F. Paoletti | Maria Filomena Paoletti
[1] Vladimir R Muzykantov,et al. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes , 2003, Nature Biotechnology.
[2] C Lizano,et al. In vitro study of alcohol dehydrogenase and acetaldehyde dehydrogenase encapsulated into human erythrocytes by an electroporation procedure. , 1998, Biochimica et biophysica acta.
[3] Mehrdad Hamidi,et al. Applications of carrier erythrocytes in delivery of biopharmaceuticals. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[4] J. Deloach. Dialysis method for entrapment of proteins into resealed red blood cells. , 1987, Methods in Enzymology.
[5] R. Desnick,et al. Enzyme therapy. V. In vivo fate of erythrocyte-entrapped beta-glucuronidase in beta-glucuronidase-deficient mice. , 1975, Pediatric Research.
[6] J. L. Way,et al. In vivo studies on rhodanese encapsulation in mouse carrier erythrocytes. , 1991, Toxicology and applied pharmacology.
[7] H. Simmonds,et al. Carrier erythrocyte entrapped adenosine deaminase therapy in adenosine deaminase deficiency. , 2000, Advances in Experimental Medicine and Biology.
[8] G. Rodriguez. Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma. , 1994, Investigational new drugs.
[9] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[10] M. Muqit,et al. CARRIER ERYTHROCYTE ENTRAPPED THYMIDINE PHOSPHORYLASE THERAPY FOR MNGIE , 2008, Neurology.
[11] Cheol Moon,et al. L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[12] S. Updike,et al. Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences. , 1983, The Journal of laboratory and clinical medicine.
[13] M. Pinilla,et al. In vitro and in vivo study of glutamate dehydrogenase encapsulated into mouse erythrocytes by a hypotonic dialysis procedure. , 1999, Life sciences.
[14] W J Jusko,et al. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[15] Minnie Sarwal,et al. Calcineurin Inhibitor Nephrotoxicity , 2012 .
[16] M. Magnani,et al. Cell-based drug delivery. , 2008, Advanced drug delivery reviews.
[17] G. Damonte,et al. Azidothymidine homodinucleotide-loaded erythrocytes and bioreactors for slow delivery of the antiretroviral drug azidothymidine. , 1996, Biochemical and biophysical research communications.
[18] A. Andriulli,et al. Erythrocytes-Mediated Delivery of Dexamethasone in Steroid-Dependent IBD Patients—A Pilot Uncontrolled Study , 2005, The American Journal of Gastroenterology.
[19] W. Satterfield,et al. Intraperitoneal administration of carrier erythrocytes in dogs: an improved method for delivery of L‐asparaginase , 1990, Biotechnology and applied biochemistry.
[20] S. Snyder,et al. The 13-kD FK506 Binding Protein, FKBP13, Interacts with a Novel Homologue of the Erythrocyte Membrane Cytoskeletal Protein 4.1 , 1998, The Journal of cell biology.
[21] L Bigi,et al. Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease , 2001, Biotechnology and applied biochemistry.
[22] N. Zaffaroni,et al. Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines. , 2010, International journal of oncology.
[23] Mauro Magnani,et al. Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: case report. , 2006, Journal of pediatric gastroenterology and nutrition.
[24] Nolan H. Sigal,et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin , 1989, Nature.
[25] M. Magnani,et al. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[26] A. Batlle,et al. Enzyme replacement therapy in porphyrias--IV. First successful human clinical trial of delta-aminolevulinate dehydratase-loaded erythrocyte ghosts. , 1983, The International journal of biochemistry.
[27] M. Magnani,et al. Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity. , 1989, Biochemical and biophysical research communications.
[28] J. L. Way,et al. Erythrocytes as Drug Carriers in Medicine , 1997, Springer US.
[29] R H Glew,et al. Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Iwaki,et al. Encapsulation of human urokinase in rabbit erythrocytes and its disposition in the circulation system in rabbits. , 1987, Journal of pharmacobio-dynamics.
[31] E. Beutler,et al. Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. Broeckhoven,et al. Hyperargininemia: the rat as a model for the human disease and the comparative response to enzyme replacement therapy with free arginase and arginase-loaded erythrocytes in vivo. , 1984, International Journal of Biochemistry.
[33] S. Barik. Immunophilins: for the love of proteins , 2006, Cellular and Molecular Life Sciences CMLS.
[34] M. Laguerre,et al. Acetaldehyde dehydrogenase-loaded erythrocytes as bioreactors for the removal of blood acetaldehyde. , 1989, Alcoholism, clinical and experimental research.
[35] M Cutolo,et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data , 2005, Annals of the rheumatic diseases.
[36] M. Magnani,et al. Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes. , 1996, Biochimica et biophysica acta.
[37] M. Laguerre,et al. Erythrocytes as Carriers for L‐Asparaginase. Methodological and Mouse In‐vivo Studies , 1990, The Journal of pharmacy and pharmacology.
[38] G. Damonte,et al. Red Blood Cells as a Delivery System for AZT , 1995 .
[39] B. Chabner. Pharmacologic principles of cancer treatment , 1982 .
[40] D. Atochin,et al. Cerebrovascular Thromboprophylaxis in Mice by Erythrocyte-Coupled Tissue-Type Plasminogen Activator , 2008, Circulation.
[41] H. Dengler,et al. Characterization of cyclosporine a uptake in human erythrocytes , 2004, European Journal of Clinical Pharmacology.
[42] B. Bax,et al. In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol‐conjugated and native adenosine deaminase , 2000, British journal of haematology.
[43] M. Magnani,et al. Comparison of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation. , 1992, Advances in experimental medicine and biology.
[44] M. Magnani,et al. Red Blood Cells as a Glucocorticoids Delivery System , 1997 .
[45] F. Aweeka,et al. Drug Concentration Monitoring of Immunosuppressive Agents , 2000, BioDrugs.
[46] M. Magnani,et al. The Use of Resealed Erythrocytes as Carriers and Bioreactors , 1992, Advances in Experimental Medicine and Biology.
[47] Gianluca Damonte,et al. Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients. , 2004, Blood cells, molecules & diseases.
[48] 이현주,et al. ADRENOCORTICOTROPIC hormone. , 1951, Lancet.
[49] J. L. Way,et al. Encapsulation of phosphotriesterase within murine erythrocytes. , 1994, Toxicology and applied pharmacology.
[50] J. Davison,et al. Drug Safety Issues in Pregnancy Following Transplantation and Immunosuppression , 1998, Drug safety.
[51] E. Zocchi,et al. Conversion of encapsulated 5-fluoro-2'-deoxyuridine 5'-monophosphate to the antineoplastic drug 5-fluoro-2'-deoxyuridine in human erythrocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[52] Vladimir R Muzykantov,et al. Drug delivery by red blood cells: vascular carriers designed by mother nature , 2010, Expert opinion on drug delivery.
[53] J. L. Way,et al. Rhodanese and sodium thiosulfate encapsulated in mouse carrier erythrocytes. II. In vivo survivability and alterations in physiologic and morphologic characteristics. , 1991, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[54] G. Sudlow,et al. Further characterization of specific drug binding sites on human serum albumin. , 1976, Molecular pharmacology.
[55] L. Mchale,et al. Encapsulation of the thrombolytic enzyme, brinase, in photosensitized erythrocytes: a novel thrombolytic system based on photodynamic activation. , 1994, Journal of photochemistry and photobiology. B, Biology.
[56] S. Schreiber,et al. A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase , 1989, Nature.
[57] R. Sheeladevi,et al. Detoxification of formate by formate dehydrogenase-loaded erythrocytes and carbicarb in folate-deficient methanol-intoxicated rats. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[58] Benjamin A. Shoemaker,et al. Knowledge-based annotation of small molecule binding sites in proteins , 2010, BMC Bioinformatics.
[59] Tipton Kf,et al. The influence of enzyme concentration on the encapsulation of glutamate dehydrogenase and alcohol dehydrogenase in red blood cells , 1995, Biotechnology and applied biochemistry.
[60] R. Kershner,et al. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. , 1996, Transplantation.
[61] F. Aweeka,et al. Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. , 2000, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[62] P. Ind,et al. A 9‐yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult‐type ADA deficiency , 2007, European journal of haematology.
[63] A. Tanaka. [A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[64] V. Muzykantov,et al. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[65] D. Lewis,et al. Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. , 1985, Biochemical pharmacology.
[66] Gianluca Damonte,et al. Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study , 2008, The American Journal of Gastroenterology.
[67] R. Glew,et al. Enzymatic degradation of uric acid by uricase-loaded human erythrocytes. , 1975, The Journal of clinical investigation.
[68] S. Curry,et al. Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.
[69] X. Barril,et al. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. , 2010, Journal of medicinal chemistry.
[70] M. Magnani,et al. Long-term Treatment With Autologous Red Blood Cells Loaded With Dexamethasone 21–Phosphate in Pediatric Patients Affected by Steroid-dependent Crohn Disease , 2007, Journal of pediatric gastroenterology and nutrition.
[71] J. L. Way,et al. Encapsulation of thiosulfate: cyanide sulfurtransferase by mouse erythrocytes. , 1986, Toxicology and applied pharmacology.
[72] T. Philip,et al. Tolerance Evaluation of L-asparaginase loaded in red blood cells , 1996, European Journal of Clinical Pharmacology.
[73] B. Ryffel,et al. Identification of cyclophilin as the erythrocyte ciclosporin-binding protein. , 1988, Biochimica et biophysica acta.